A double-edged hormone: The moderating role of personality and attachment on oxytocin's treatment facilitation effect.

Tzur Bitan D, Grossman-Giron A, Sedoff O, Zilcha-Mano S, Nitzan U, Maoz H

Psychoneuroendocrinology27 Feb 2023Cited by 3 (Europe PMC)

PMID36905736DOI10.1016/j.psyneuen.2023.106074PepBankPUB-36905736

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In inpatients with severe mental illness, oxytocin was associated with improved depression in patients low in openness versus placebo.
In plain wordsIn hospitalized patients with severe mental illness, oxytocin was linked to less depression in those low in openness, compared with placebo.
Peptide
Oxytocin
Outcome
DecreaseDepression in patients low in openness
Study
n: not reported in source
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
B
2.12 NA
depression, low openness
Source sentences
Summary
Oxytocin administration was significantly associated with improvement of depression (B=2.12, SE=0.82, t = 2.56, p = .012), and suicidal ideation (B=0.03, SE=0.01, t = 2.44, p = .016) for patients low in openness
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (N = 87) were randomly assigned to receive oxytocin or placebo, as an add-on to psychotherapy for a period of four weeks, in two inpatient units.
Report a problemFND-3690573601
02HumanRandomized controlled trialEfficacy outcome
In inpatients with severe mental illness, oxytocin was associated with improved suicidal ideation in patients low in extraversion versus placebo.
In plain wordsIn hospitalized patients with severe mental illness, oxytocin was linked to less suicidal thinking in those low in extraversion, compared with placebo.
Peptide
Oxytocin
Outcome
DecreaseSuicidal ideation in patients low in extraversion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
B
0.03 NA
suicidal ideation, low extraversion
Source sentences
Summary
and suicidal ideation (B=0.03, SE=0.01, t = 2.44, p = .016) for patients low in openness and extraversion, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (N = 87) were randomly assigned to receive oxytocin or placebo, as an add-on to psychotherapy for a period of four weeks, in two inpatient units.
Report a problemFND-3690573602
03HumanRandomized controlled trialEfficacy outcome
In inpatients with severe mental illness, oxytocin was associated with a worse working alliance in patients high in extraversion versus placebo.
In plain wordsIn hospitalized patients with severe mental illness, oxytocin was linked to a weaker bond with the therapist in those high in extraversion, compared with placebo.
Peptide
Oxytocin
Outcome
DecreaseWorking alliance in patients high in extraversion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Social behavior and cognition · Mental health and mood
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
B
−0.11 NA
working alliance, high extraversion
Source sentences
Summary
oxytocin administration was also significantly associated with a deterioration in the working alliance for patients high in extraversion (B=-0.11, SE=0.04, t = -2.73, p = .007)
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (N = 87) were randomly assigned to receive oxytocin or placebo, as an add-on to psychotherapy for a period of four weeks, in two inpatient units.
Report a problemFND-3690573603
04HumanRandomized controlled trialEfficacy outcome
In inpatients with severe mental illness, oxytocin was associated with a worse working alliance in patients low in neuroticism versus placebo.
In plain wordsIn hospitalized patients with severe mental illness, oxytocin was linked to a weaker bond with the therapist in those low in neuroticism, compared with placebo.
Peptide
Oxytocin
Outcome
DecreaseWorking alliance in patients low in neuroticism
Study
n: not reported in source
Comparator
Placebo
Outcome group
Social behavior and cognition · Mental health and mood
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
B
0.08 NA
working alliance, low neuroticism
Source sentences
Summary
low in neuroticism (B=0.08, SE=0.03, t = 2.01, p = .047)
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (N = 87) were randomly assigned to receive oxytocin or placebo, as an add-on to psychotherapy for a period of four weeks, in two inpatient units.
Report a problemFND-3690573604
05HumanRandomized controlled trialEfficacy outcome
In inpatients with severe mental illness, oxytocin was associated with a worse working alliance in patients low in agreeableness versus placebo.
In plain wordsIn hospitalized patients with severe mental illness, oxytocin was linked to a weaker bond with the therapist in those low in agreeableness, compared with placebo.
Peptide
Oxytocin
Outcome
DecreaseWorking alliance in patients low in agreeableness
Study
n: not reported in source
Comparator
Placebo
Outcome group
Social behavior and cognition · Mental health and mood
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
B
0.11 NA
working alliance, low agreeableness
Source sentences
Summary
and low in agreeableness (B=0.11, SE=0.04, t = 2.76, p = .007)
1 context sentence(design, population, supporting numbers)
Summary · context
Patients (N = 87) were randomly assigned to receive oxytocin or placebo, as an add-on to psychotherapy for a period of four weeks, in two inpatient units.
Report a problemFND-3690573605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT03566069

Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness

Shalvata Mental Health Centern = 1201 Jun 2018 to est. Jun 2025

Severe Mental Illness

Trial page ClinicalTrials.govUpdated 28 Jun 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.